(Q21559486)

English

Atorvastatin added to interferon beta for relapsing multiple sclerosis: 12-month treatment extension of the randomized multicenter SWABIMS trial

scientific article

Atorvastatin Added to Interferon Beta for Relapsing Multiple Sclerosis: 12-Month Treatment Extension of the Randomized Multicenter SWABIMS Trial

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

0 references

Atorvastatin added to interferon beta for relapsing multiple sclerosis: 12-month treatment extension of the randomized multicenter SWABIMS trial (English)

0 references

multicenter clinical trial

0 references

multiple sclerosis

0 references

11

object named as

Ludwig Kappos

author given names

Ludwig

author last names

Kappos

1 reference

PubMed publication ID

3 September 2022

5

author given names

Yuliya

author last names

Burren

object named as

Yuliya Burren

1 reference

PubMed publication ID

3 September 2022

Marwan El-Koussy

2

author given names

Marwan

author last names

El-Koussy

object named as

Marwan El-Koussy

1 reference

PubMed publication ID

3 September 2022

Heinrich Mattle

13

author given names

Heinrich P

author last names

Mattle

object named as

Heinrich P Mattle

1 reference

PubMed publication ID

3 September 2022

author name string

Christian P Kamm

1

author given names

Christian P

author last names

Kamm

1 reference

PubMed publication ID

3 September 2022

Sebastian Humpert

3

author given names

Sebastian

author last names

Humpert

1 reference

PubMed publication ID

3 September 2022

Oliver Findling

4

author given names

Oliver

author last names

Findling

1 reference

PubMed publication ID

3 September 2022

Guido Schwegler

6

author given names

Guido

author last names

Schwegler

1 reference

PubMed publication ID

3 September 2022

Filippo Donati

7

author given names

Filippo

author last names

Donati

1 reference

PubMed publication ID

3 September 2022

Martin Müller

8

author given names

Martin

author last names

Müller

1 reference

PubMed publication ID

3 September 2022

Felix Müller

9

author given names

Felix

author last names

Müller

1 reference

PubMed publication ID

3 September 2022

Johannes Slotboom

10

author given names

Johannes

author last names

Slotboom

1 reference

PubMed publication ID

3 September 2022

Yvonne Naegelin

12

author given names

Yvonne

author last names

Naegelin

1 reference

PubMed publication ID

3 September 2022

language of work or name

0 references

publication date

2014

0 references

0 references

9

0 references

1

0 references

e86663

0 references

copyright license

Creative Commons Attribution 4.0 International

30 January 2014

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

Vascular comorbidity is associated with more rapid disability progression in multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3907426

19 March 2017

Oral high-dose atorvastatin treatment in relapsing-remitting multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3907426

19 March 2017

Statins for multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3907426

19 March 2017

Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3907426

19 March 2017

The immunopathology of multiple sclerosis: an overview

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3907426

19 March 2017

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3907426

19 March 2017

Unified segmentation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3907426

7 April 2017

Efficacy of statins in combination with interferon therapy in multiple sclerosis: a meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3907426

12 September 2017

Inhibition of interferon-beta responses in multiple sclerosis immune cells associated with high-dose statins

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3907426

12 September 2017

Atorvastatin added to interferon β for relapsing multiple sclerosis: a randomized controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3907426

12 September 2017

Therapeutic potential of statins in multiple sclerosis: immune modulation, neuroprotection and neurorepair

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3907426

12 September 2017

SWiss Atorvastatin and interferon Beta-1b trial In Multiple Sclerosis (SWABIMS)--rationale, design and methodology

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3907426

12 September 2017

Effect of statins on clinical and molecular responses to intramuscular interferon beta-1a

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3907426

12 September 2017

Statin therapy inhibits remyelination in the central nervous system.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3907426

12 September 2017

Comorbidity delays diagnosis and increases disability at diagnosis in MS.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3907426

12 September 2017

Cross-validation of brain segmentation by SPM5 and SIENAX.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3907426

12 September 2017

Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3907426

12 September 2017

Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3907426

12 September 2017

The Multiple Sclerosis Functional Composite Measure (MSFC): an integrated approach to MS clinical outcome assessment. National MS Society Clinical Outcomes Assessment Task Force

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3907426

12 September 2017

Effect of pravastatin on outcomes after cardiac transplantation.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0086663

21 January 2018

Lovastatin treatment decreases mononuclear cell infiltration into the CNS of Lewis rats with experimental allergic encephalomyelitis

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0086663

21 January 2018

The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0086663

21 January 2018

Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0086663

21 January 2018

Atorvastatin combined to interferon to verify the efficacy (ACTIVE) in relapsing-remitting active multiple sclerosis patients: a longitudinal controlled trial of combination therapy

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0086663

21 January 2018

Simvastatin as add-on therapy to interferon β-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0086663

21 January 2018

A novel method for analyzing DSCE-images with an application to tumor grading

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0086663

21 January 2018

Negative impact of statins on oligodendrocytes and myelin formation in vitro and in vivo.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0086663

21 January 2018

Statins as immunomodulators: comparison with interferon-beta 1b in MS.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0086663

21 January 2018

Different effects of simvastatin and interferon beta on the proteolytic activity of matrix metalloproteinases

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0086663

21 January 2018

Oral simvastatin treatment in relapsing-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0086663

21 January 2018

WHO Expert Committee on Biological Standardization. Thirty-fifth report

1 reference

https://pubmed.ncbi.nlm.nih.gov/24497963

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/24497963

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomisation in clinical trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/24497963

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Amelioration of experimental allergic encephalomyelitis in Lewis rats by lovastatin

1 reference

https://pubmed.ncbi.nlm.nih.gov/24497963

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1371/JOURNAL.PONE.0086663

0 references

2014PLoSO...986663K

0 references

PMC publication ID

0 references

PubMed publication ID

0 references

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q21559486&oldid=1980561343"